Table 5.

Summary of previous studies for the investigation of the efficacy of third-line eradication therapy for H. pylori infection.

First author [ref. no.]s	Year	Method		VPZ-containing eradication regimen			PPI-containing eradication regimen
				Number	Regimen	Eradication rate	Number	Regimen	Eradication rate
Sugimoto (Sugimoto et al., 2017)	2017	OS	ITT	15	VPZ: 20 mg bid AMX: 500 mg qid STFX: 100 mg bid	80.0%
Sue (Sue et al., 2018b)	2018	RCT	ITT	33	VPZ: 20 mg bid AMX: 750 mg bid STFX: 100 mg bid	75.8%	30	LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid STFX: 100 mg bid	53.3%

All paper to investigate efficacy of third-line vonoprazan-containing eradication therapy up until September 2018 were listed. AMX, amoxicillin; bid, twice daily dosing; EPZ, esomeprazole; ITT, intention to treat analysis; LPZ, lansoprazole; MNZ, metronidazole; PPI, proton pump inhibitor; OS, observational study; qid, four times daily dosing; RCT, randomized control trial; RST, retrospective cohort trial; RPZ, rabeprazole; STFX, sitafloxacin; VPZ, vonoprazan.